共 50 条
Contemporary Concise Review 2022: Interstitial lung disease
被引:2
|作者:
Smith, David J. F.
[1
,2
]
Jenkins, R. Gisli
[1
,2
]
机构:
[1] Imperial Coll London, Natl Heart & Lung Inst, London, England
[2] Guys & St ThomasNHS Fdn Trust, Royal Brompton & Harefield Hosp, Dept Interstitial Lung Dis, London, England
来源:
关键词:
biomarkers;
COVID;
fibroblast;
idiopathic pulmonary fibrosis;
interstitial lung disease;
IDIOPATHIC PULMONARY-FIBROSIS;
CLINICAL-PRACTICE;
DOUBLE-BLIND;
EFFICACY;
EXACERBATION;
PIRFENIDONE;
MULTICENTER;
PROGRESSION;
SAFETY;
D O I:
10.1111/resp.14511
中图分类号:
R56 [呼吸系及胸部疾病];
学科分类号:
摘要:
OF KEY POINTSNovel genetic associations for idiopathic pulmonary fibrosis (IPF) risk have been identified. Common genetic variants associated with IPF are also associated with chronic hypersensitivity pneumonitis.The characterization of underlying mechanisms, such as pathways involved in myofibroblast differentiation, may reveal targets for future treatments.Newly identified circulating biomarkers are associated with disease progression and mortality.Deep learning and machine learning may increase accuracy in the interpretation of CT scans.Novel treatments have shown benefit in phase 2 clinical trials.Hospitalization with COVID-19 is associated with residual lung abnormalities in a substantial number of patients.Inequalities exist in delivering and accessing interstitial lung disease specialist care.
引用
收藏
页码:627 / 635
页数:9
相关论文